GB00BMVP7Y09 - Common Stock
ROYALTY PHARMA PLC- CL A
NASDAQ:RPRX (3/27/2024, 8:00:03 PM)
After market: 30.45 0 (0%)30.45
+0.22 (+0.73%)
Royalty Pharma Plc provides drug development services. The company is headquartered in New York City, New York and currently employs 75 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products, including Vertexs Trikafta, Kalydeco, Orkambi and Symdeko, Biogens Tysabri, AbbVie and Johnson & Johnsons Imbruvica, Astellas and Pfizer's Xtandi, GSKs Trelegy, Novartis Promacta, Pfizer's Nurtec ODT, Johnson & Johnsons Tremfya, Roches Evrysdi, Gilead's Trodelvy, and 12 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Olpasiran, Omecamtiv mecarbil, Pelabresib, Pelacarsen, Seltorexant, Trontinemab, Tulmimetostat and Zavegepant. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
ROYALTY PHARMA PLC- CL A
110 East 59th Street
New York City NEW YORK 10022
P: 12128830200
CEO: Pablo Legorreta
Employees: 75
Website: https://www.royaltypharma.com
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s...
Analysts are quite bullish about these beaten-down stocks.
Royalty Pharma press release (RPRX): Q4 net income of $718M Revenue of $596M (+5.3% Y/Y) misses by $78.54M. More on Royalty Pharma Royalty Pharma: One Of The Be
Here you can normally see the latest stock twits on RPRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: